This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Kittipong Maneechotesuwan, Mahidol University
ClinicalTrials.gov Identifier:
NCT00792337
First received: November 14, 2008
Last updated: September 10, 2013
Last verified: September 2009
November 14, 2008
September 10, 2013
December 2008
August 2009   (Final data collection date for primary outcome measure)
Sputum eosinophil [ Time Frame: 8 WEEKS ]
Same as current
Complete list of historical versions of study NCT00792337 on ClinicalTrials.gov Archive Site
  • FEV1 [ Time Frame: 8 WEEKS ]
  • PC20 [ Time Frame: 8 weeks ]
Same as current
Not Provided
Not Provided
 
The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma
The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids in Asthma
We hypothesize that simvastatin in combination with ICS might have synergistic anti-inflammatory effects on airway inflammation in asthmatic patients
To determine the additive effect of simvastatin on airway inflammation in ICS-treated patients with persistent asthma by measuring eosinophil counts in induced sputum
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Asthma
  • Drug: simvastatin
    10 mg per oral once daily for 8 weeks
    Other Name: zocor
  • Drug: B1-6-12
    1 table per day for 8 weeks
    Other Name: vitamin B1-6-12
  • Active Comparator: simvastatin
    simvastatin in combination with budesonide
    Intervention: Drug: simvastatin
  • Placebo Comparator: B1-6-12
    Budesonide in combination with B1-6-12
    Intervention: Drug: B1-6-12
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
53
September 2009
August 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • He or she has FEV1 > 60% of predicted
  • He or she requires less than 1000 mcg daily of beclomethasone or equivalent

Exclusion Criteria:

  • He or she had previous history of renal disease or serum creatinine more than 2 mg/dL
  • He or she had previous history of liver disease
  • She is pregnant or during lactation
  • He or she has already received statins or is allergic to statins or has developed myositis.
  • He or she has an asthma exacerbation and requires treatment with oral corticosteroids during the 3 months prior to the commencement of study entry.
Sexes Eligible for Study: All
18 Years to 70 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Thailand
 
 
NCT00792337
004(II)/51
No
Not Provided
Not Provided
Kittipong Maneechotesuwan, Mahidol University
Mahidol University
Not Provided
Principal Investigator: Kittipong - Maneechotesuwan, MD, PhD Faculty of Medicine Siriraj Hospital
Mahidol University
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP